Moloney Securities Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $3.05M | Buy |
13,182
+201
| +2% | +$40.9K | 0.36% | 63 |
|
|
2025
Q2 | $2.41M | Buy |
12,981
+197
| +2% | +$36.6K | 0.3% | 71 |
|
|
2025
Q1 | $2.68M | Sell |
12,784
-9,296
| -42% | -$1.81M | 0.36% | 60 |
|
|
2024
Q4 | $3.92M | Sell |
22,080
-265
| -1% | -$48.7K | 0.53% | 48 |
|
|
2024
Q3 | $4.41M | Buy |
22,345
+554
| +3% | +$103K | 0.59% | 39 |
|
|
2024
Q2 | $3.74M | Sell |
21,791
-3,061
| -12% | -$507K | 0.54% | 42 |
|
|
2024
Q1 | $4.53M | Sell |
24,852
-1,678
| -6% | -$289K | 0.68% | 34 |
|
|
2023
Q4 | $4.11M | Sell |
26,530
-1,189
| -4% | -$173K | 0.65% | 33 |
|
|
2023
Q3 | $4.13M | Buy |
27,719
+8
| +0% | +$1.17K | 0.74% | 27 |
|
|
2023
Q2 | $3.73M | Buy |
27,711
+686
| +3% | +$101K | 0.66% | 36 |
|
|
2023
Q1 | $4.31M | Sell |
27,025
-5,170
| -16% | -$790K | 0.8% | 19 |
|
|
2022
Q4 | $5.2M | Sell |
32,195
-299
| -0.9% | -$45.8K | 1.15% | 10 |
|
|
2022
Q3 | $4.36M | Sell |
32,494
-1,040
| -3% | -$149K | 1.06% | 18 |
|
|
2022
Q2 | $5.14M | Sell |
33,534
-65
| -0.2% | -$9.93K | 1.2% | 12 |
|
|
2022
Q1 | $5.45M | Buy |
33,599
+102
| +0.3% | +$14.8K | 1.06% | 15 |
|
|
2021
Q4 | $4.54M | Sell |
33,497
-137
| -0.4% | -$16.2K | 0.77% | 22 |
|
|
2021
Q3 | $3.63M | Buy |
33,634
+1,083
| +3% | +$124K | 0.66% | 36 |
|
|
2021
Q2 | $3.67M | Buy |
32,551
+4,490
| +16% | +$506K | 0.67% | 37 |
|
|
2021
Q1 | $3.04M | Sell |
28,061
-5,133
| -15% | -$549K | 0.6% | 45 |
|
|
2020
Q4 | $3.56M | Sell |
33,194
-452
| -1% | -$43.4K | 0.79% | 27 |
|
|
2020
Q3 | $2.95M | Sell |
33,646
-316
| -0.9% | -$29.8K | 0.78% | 34 |
|
|
2020
Q2 | $3.33M | Sell |
33,962
-138
| -0.4% | -$12.2K | 0.97% | 22 |
|
|
2020
Q1 | $2.6M | Buy |
34,100
+3,326
| +11% | +$283K | 0.93% | 25 |
|
|
2019
Q4 | $2.73M | Sell |
30,774
-224
| -0.7% | -$18.6K | 0.84% | 27 |
|
|
2019
Q3 | $2.35M | Buy |
30,998
+284
| +0.9% | +$19.5K | 0.78% | 30 |
|
|
2019
Q2 | $2.23M | Sell |
30,714
-409
| -1% | -$32.1K | 0.75% | 33 |
|
|
2019
Q1 | $2.51M | Buy |
31,123
+2,934
| +10% | +$240K | 0.87% | 26 |
|
|
2018
Q4 | $2.6M | Sell |
28,189
-2,892
| -9% | -$254K | 1.06% | 22 |
|
|
2018
Q3 | $2.94M | Buy |
31,081
+391
| +1% | +$37.1K | 1.02% | 19 |
|
|
2018
Q2 | $2.84M | Buy |
30,690
+1,395
| +5% | +$136K | 1.08% | 16 |
|
|
2018
Q1 | $2.77M | Sell |
29,295
-1,630
| -5% | -$179K | 1.12% | 13 |
|
|
2017
Q4 | $2.99M | Sell |
30,925
-4,163
| -12% | -$392K | 1.26% | 15 |
|
|
2017
Q3 | $3.12M | Buy |
35,088
+11,930
| +52% | +$908K | 1.39% | 15 |
|
|
2017
Q2 | $1.68M | Buy |
23,158
+2,227
| +11% | +$150K | 0.84% | 28 |
|
|
2017
Q1 | $1.36M | Buy |
20,931
+3,769
| +22% | +$237K | 0.71% | 38 |
|
|
2016
Q4 | $1.07M | Buy |
+17,162
| New | +$1.05M | 0.65% | 36 |
|
Other funds holding ABBV
Moloney Securities Asset Management's ABBV Position: Q3 2025 in Review
Moloney Securities Asset Management increased its AbbVie (ABBV) stake by 1.5% in Q3 2025, buying an estimated $40.9K and bringing the position to 13,182 shares worth $3.05M. The position accounts for 0.36% of the portfolio, ranked #63.
Moloney Securities Asset Management first reported a position in ABBV in Q4 2016 and has held it in 36 quarters since. The position peaked at $5.45M in Q1 2022. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- Moloney Securities Asset Management held 13,182 shares of AbbVie worth $3.05M as of Q3 2025.
- Moloney Securities Asset Management bought 201 AbbVie shares in Q3 2025, an estimated $40.9K.
- AbbVie made up 0.36% of Moloney Securities Asset Management's portfolio in Q3 2025, its #63 holding.
- Moloney Securities Asset Management first reported a position in AbbVie in Q4 2016 and has held it in 36 quarters since.
- Moloney Securities Asset Management's AbbVie position peaked at $5.45M in Q1 2022.
- 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.